Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 299-306

  Tesfai, Yordanos ^a   Ford, Jette ^a   Carter, Kim W ^a   Firth, Martin J ^a   O'Leary, Rebecca A ^a   Gottardo, Nicholas G ^a,b   Cole, Catherine ^b,c   Kees, Ursula R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Acute lymphoblastic leukemia; Bone marrow; Gene expression; Microenvironment; Therapy

Indexed keywords

ASPARAGINASE; CD34 ANTIGEN; CYTARABINE; DEXAMETHASONE; OLIGONUCLEOTIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; BMP 2 GENE; BONE MARROW CELL; CANCER RESISTANCE; CELL COMMUNICATION; CELL INTERACTION; CELL MOTILITY; COHORT ANALYSIS; CONTROLLED STUDY; CTGF GENE; CXCR4 GENE; CYTOGENETICS; GENE CONTROL; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IL7R GENE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REGULATOR GENE; SIGNAL TRANSDUCTION; STROMA CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANTIGENS, CD34; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPARAGINASE; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL COMMUNICATION; CELL SURVIVAL; CELLS, CULTURED; CHILD; COHORT STUDIES; CYTARABINE; DEXAMETHASONE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84855950079     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.001     Document Type: Article

References (34)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371(9617):1030-1043.
2. Nguyen K., Devidas M., Cheng S.C., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008, 22(12):2142-2150.
3. Borowitz M.J., Devidas M., Hunger S.P., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008, 111(12):5477-5485.
4. Flohr T., Schrauder A., Cazzaniga G., et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008, 22(4):771-782.
5. Yeoh E.-J., Ross M.E., Shurtleff S.A., et al. Classification, sybtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1(March 2002):133-143.
6. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114(6):1150-1157.
7. Boag J.M., Beesley A.H., Firth M.J., et al. High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br J Haematol 2007, 138(6):740-748.
8. Boag J.M., Beesley A.H., Firth M.J., et al. Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia. Leukemia 2006, 20(10):1731-1737.
9. Ross M.E., Zhou X., Song G., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102(8):2951-2959.
10. Beesley A.H., Palmer M.L., Ford J., et al. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer 2006, 95(11):1537-1544.
11. Roecklein B.A., Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995, 85(4):997-1005.
12. Beesley A.H., Cummings A.J., Freitas J.R., et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol 2005, 131(4):447-456.
13. Subramanian A., Kuehn H., Gould J., Tamayo P., Mesirov J.P. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007, 23(23):3251-3253.
14. Hystad M.E., Myklebust J.H., Bo T.H., et al. Characterization of early stages of human B cell development by gene expression profiling. J Immunol 2007, 179(6):3662-3671.
15. Samudio I., Fiegl M., McQueen T., Clise-Dwyer K., Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008, 68(13):5198-5205.
16. Wei J., Wunderlich M., Fox C., et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 2008, 13(6):483-495.
17. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446(7137):758-764.
18. Yu Q., Erman B., Park J.H., Feigenbaum L., Singer A. IL-7 receptor signals inhibit expression of transcription factors TCF-1, LEF-1, and RORgammat: impact on thymocyte development. J Exp Med 2004, 200(6):797-803.
19. Cobaleda C., Schebesta A., Delogu A., Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007, 8(5):463-470.
20. Fazio G., Palmi C., Rolink A., Biondi A., Cazzaniga G. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells. Cancer Res 2008, 68(1):181-189.
21. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455(7211):406-410.
22. Mudry R.E., Fortney J.E., York T., Hall B.M., Gibson L.F. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000, 96(5):1926-1932.
23. Iwamoto S., Mihara K., Downing J.R., Pui C.H., Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007, 117(4):1049-1057.
24. Beesley A.H., Weller R.E., Kees U.R. The role of BSG (CD147) in acute lymphoblastic leukaemia and relapse. Br J Haematol 2008, 142(6):1000-1002.
25. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359(22):2313-2323.
26. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23(1):43-52.
27. Brigstock D.R. The CCN family: a new stimulus package. J Endocrinol 2003, 178(2):169-175.
28. Kang H., Chen I.M., Wilson C.S., et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010, 115(7):1394-1405.
29. Sala-Torra O., Gundacker H.M., Stirewalt D.L., et al. Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood 2007, 109(7):3080-3083.
30. Planque N., Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003, 3(1):15.
31. Bennewith K.L., Huang X., Ham C.M., et al. The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 2009, 69(3):775-784.
32. Noren-Nystrom U., Roos G., Bergh A., et al. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia 2008, 22(3):504-510.
33. Aikawa T., Gunn J., Spong S.M., Klaus S.J., Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 2006, 5(5):1108-1116.
34. Maeda A., Nishida T., Aoyama E., et al. CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J Biochem 2009, 145(2):207-216.